|Mr. Peter S. Greenleaf||Chairman & CEO||1.28M||2.02M||47|
|Dr. Peter A. Kiener Ph.D.||Chief Science Officer||699.67k||N/A||65|
|Mr. Matthew Maxwell Donley||Exec. VP of Global HR, Information Technology and Strategy||668.63k||N/A||48|
|Mr. Peter P. Pfreundschuh CPA||Chief Financial Officer||N/A||N/A||48|
|Ms. Silvia Taylor MBA||Sr. VP of Investor Relations and Corp. Affairs||N/A||N/A||N/A|
Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing, identifying, acquiring, and marketing medicines that meet unmet medical needs, primarily in gastroenterology, ophthalmology, and oncology-related disorders in the United States, Japan, Switzerland, and internationally. The companys marketed product includes AMITIZA (lubiprostone), a ClC-2 chloride channel activator for the treatment of chronic idiopathic constipation (CIC) in adults, irritable bowel syndrome with constipation in adult women (IBS-C), and opioid-induced constipation (OIC)in patients with chronic non-cancer related pain; and RESCULA (unoprostone isopropyl), a big potassium channel activator for the treatment of glaucoma and ocular hypertension. Its product candidates in clinical development stage comprise Lubiprostone that is in Phase III clinical trials for the treatment of pediatric functional constipation and (IBS-C); and completed Phase III clinical trials for the treatment of (CIC) in adults, IBS-C in adult women, and OIC in patients with chronic non-cancer pain, as well as CPP-1X/sulindac combination product, which has completed Phase III clinical trials for the treatment of familial adenomatous polyposis. The company is also developing VTS-270, which is in a pivotal Phase 2b/3 trial for the treatment of Niemann-Pick Disease Type C1. Sucampo Pharmaceuticals, Inc. was founded in 1996 is headquartered in Rockville, Maryland.
Sucampo Pharmaceuticals, Inc.’s ISS Governance QualityScore as of August 1, 2017 is 6. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 8; Compensation: 5.